Efficacy and Safety of Bepotastine Besilate in the Treatment of Chronic Urticaria

DOI Web Site Web Site 10 References

Bibliographic Information

Other Title
  • 慢性蕁麻疹に対するベシル酸ベポタスチン(タリオン<SUP>®</SUP>錠)の臨床的有用性の検討
  • 治療 慢性蕁麻疹に対するベシル酸ベポタスチン(タリオン錠)の臨床的有用性の検討
  • チリョウ マンセイ ジンマシン ニ タイスル ベシルサン ベポタスチン タリオンジョウ ノ リンショウテキ ユウヨウセイ ノ ケントウ

Search this article

Abstract

The efficacy and safety of bepotastine besilate (Talion®) in the treatment of chronic urticaria were evaluated in 88 adult patients with chronic urticaria. Patients were openly treated with 20 mg/day oral bepotastine besilate for 14 days. Clinical evaluations were performed every 7 days, and patients were asked to keep a diary, recording their pruritus scores. Symptoms improved in 77.1% of the patients after two weeks and pruritus scores were reduced significantly within 24 h after oral administration in 69.6% of patients. It appears that bepotastine besilate can be ranked as a drug of first choice for the treatment of chronic urticaria, because it rapidly relieved itch and the incidence of drowsiness was relatively low.

Journal

  • Nishi Nihon Hifuka

    Nishi Nihon Hifuka 68 (1), 69-75, 2006

    Western Division of Japanese Dermatological Association

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top